Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Outcomes of stem cell boost (SCB) versus supportive care alone for prolonged cytopenias after chimeric antigen receptor T cell therapy (CAR-T) in relapsed/refractory multiple myeloma (RRMM): A muli-center real-world analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

CVCindy VargaMRMyra RobinsonCWCharlotte B Wagner

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows stem cell boost improves hemoglobin and progression-free survival in multiple myeloma patients with prolonged cytopenias post CAR-T, suggesting enhanced recovery benefits.

Key Points

  • Hematologic recovery was promoted in 97.4% of patients receiving stem cell boost by day 90 post CAR-T infusion, leading to significant improvements.
  • At day 90, SCB patients had higher absolute neutrophil counts (2.12 vs. 1.59) and hemoglobin levels (10.6 vs. 8.7), indicating better outcomes compared to controls.
  • Progression-free survival was nearly doubled in SCB patients receiving ide-cel treatment, although results were limited by small sample sizes.
  • The study highlights the potential benefits of integrating stem cell boost into CAR-T therapy for patients facing prolonged cytopenias.

Cite This Study

Varga et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d44fhttps://doi.org/10.1182/blood-2025-1035
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Modified beac as bridging/lymphodepletion therapy followed by CAR-T and autologous stem cell support in relapsed or refractory DLBCL patients: Insights from safety and efficacy outcomes in 12 patients2025
  2. 2CAR T-cell therapy versus autologous HSCT in patients with large B-cell lymphoma in complete remission: An analysis from the EBMT lymphoma working party2025 · 1 citations
  3. 3Real-world comparison of CAR T-cell therapy versus bispecific antibodies in relapsed or refractory multiple myeloma2025 · 1 citations
  4. 4Sequential CD19/CD22 CAR-T cell therapy following ASCT shows improved efficacy versus CAR-t alone in relapsed/refractory large B-cell lymphoma2025
  5. 5Duration of lymphopenia after CAR-T cell therapy is associated with increased risk of non-melanoma skin cancers and decreased survival2025